what will the paper money of the future be like, snippets

Anhui's first high-growth industrial bond was successfully issued in Shanghai. Recently, Anhui Wantong Expressway Co., Ltd. (referred to as "Wantong Expressway") completed the issuance of Anhui's first high-growth industrial bond in Shanghai Stock Exchange. On October 30th this year, Wan Tong Expressway was approved by China Securities Regulatory Commission to publicly issue corporate bonds with a registered scale of no more than 5 billion yuan to professional investors.Real estate stocks are active again and again. Huayuan Real Estate and Qixia Construction both have daily limit, while Huayuan Real Estate, Qixia Construction, Xinhualian and Xinhuangpu have daily limit, while Suzhou Gaoxin, China Wuyi and Shahe shares have followed suit.Huadong Pharmaceutical has established a new company in Jiaxing with a registered capital of 60 million yuan. According to Tianyancha App, Huadong Pharmaceutical (Jiaxing) Co., Ltd. was recently established with Zhu Li as its legal representative and a registered capital of 60 million yuan. Its business scope includes drug wholesale, drug retail, decoction service for Chinese herbal pieces, third-class medical device operation, drug Internet information service, drug import and export, third-class medical device rental and medical device Internet information service. According to shareholder information, the company is wholly owned by Huadong Pharmaceutical (000963).

Huadong Pharmaceutical has established a new company in Jiaxing with a registered capital of 60 million yuan. According to Tianyancha App, Huadong Pharmaceutical (Jiaxing) Co., Ltd. was recently established with Zhu Li as its legal representative and a registered capital of 60 million yuan. Its business scope includes drug wholesale, drug retail, decoction service for Chinese herbal pieces, third-class medical device operation, drug Internet information service, drug import and export, third-class medical device rental and medical device Internet information service. According to shareholder information, the company is wholly owned by Huadong Pharmaceutical (000963).After the European Central Bank announced the interest rate decision, EUR/USD rose 15 points to 1.0484.Guoxuan Hi-Tech: China, the strategic shareholder, continued to give up voting rights. Guoxuan Hi-Tech announced that Guoxuan Holdings, Li Zhen and Jerry Lee (collectively referred to as the "founding shareholders") and China, the strategic shareholder of the company, signed a Supplementary Agreement on the Shareholders' Agreement of Guoxuan Hi-Tech Co., Ltd., and Volkswagen China agreed to extend the commitment period of giving up voting rights. That is to say, within 72 months after the relevant shares of the company involved in the non-public offering and share transfer are registered in the name of Volkswagen China or within a longer period determined by Volkswagen China, it will irrevocably give up the voting rights of some of its shares in the company, so that the voting rights of Volkswagen China will be at least 5% lower than that of the founding shareholder. Volkswagen China's extension of the period of giving up its voting rights commitment this time will not lead to the change of the company's control rights and will not affect the normal production and operation of the company. Mr. Li Zhen remains the actual controller of the company.

The legal representative of Sanzhiyang Culture Media Co., Ltd. changed. Tianyancha App showed that on December 10, Hefei Sanzhiyang Culture Media Co., Ltd. changed its business. Ba Shuai stepped down as the legal representative, executive director and general manager, and Zhang Yong was the legal representative, director and manager. The company was established in May 2022 with a registered capital of RMB 1 million. Its business scope includes radio and television program production and operation, performance brokerage, advertising, organization of cultural and artistic exchange activities, conference and exhibition services, etc. It is wholly owned by Hefei Sanzhiyang Network Technology Co., Ltd.The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)After the European Central Bank announced the interest rate decision, EUR/USD rose 15 points to 1.0484.